Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Update

Black Diamond Therapeutics, Inc. (NASDAQ:BDTXGet Free Report) saw a large drop in short interest in January. As of January 31st, there was short interest totalling 2,400,000 shares, a drop of 33.0% from the January 15th total of 3,580,000 shares. Based on an average daily volume of 528,500 shares, the days-to-cover ratio is presently 4.5 days.

Black Diamond Therapeutics Stock Up 2.6 %

Shares of BDTX stock opened at $4.34 on Tuesday. The company has a market capitalization of $224.10 million, a P/E ratio of -2.04 and a beta of 2.59. Black Diamond Therapeutics has a 12-month low of $1.22 and a 12-month high of $6.85. The firm has a 50-day moving average price of $3.03 and a 200 day moving average price of $2.87.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a report on Wednesday, November 22nd.

Check Out Our Latest Stock Report on Black Diamond Therapeutics

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its position in Black Diamond Therapeutics by 31.8% in the 1st quarter. JPMorgan Chase & Co. now owns 260,472 shares of the company’s stock worth $723,000 after purchasing an additional 62,877 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in Black Diamond Therapeutics by 376.1% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 357,100 shares of the company’s stock worth $989,000 after purchasing an additional 282,100 shares during the last quarter. BlackRock Inc. raised its position in Black Diamond Therapeutics by 3.6% in the 1st quarter. BlackRock Inc. now owns 2,329,164 shares of the company’s stock worth $6,452,000 after purchasing an additional 80,697 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Black Diamond Therapeutics by 37.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 181,097 shares of the company’s stock worth $502,000 after purchasing an additional 48,941 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Black Diamond Therapeutics by 2.8% in the 2nd quarter. Renaissance Technologies LLC now owns 272,002 shares of the company’s stock worth $669,000 after purchasing an additional 7,511 shares during the last quarter.

About Black Diamond Therapeutics

(Get Free Report)

Black Diamond Therapeutics, Inc, a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.

See Also

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.